Skip to main content
. Author manuscript; available in PMC: 2015 Jul 22.
Published in final edited form as: J Thorac Oncol. 2014 Apr;9(4):456–463. doi: 10.1097/JTO.0000000000000130

Figure 1.

Figure 1

Sequencing of the EGFR gene in the proband's adenocarcinoma revealed an activating mutation (L858R) in the EGFR gene (minor peak) (A) and a prominent T790M mutation, equal in size to the wild type peak (B). The T790M mutation substitutes methionine for threonine at position 790 (nucleotide c.2369). The finding in a lung cancer of a T790M mutant band equal in size to the wild type band prior to TKI therapy suggests a germline mutation. Examination of the proband's blood cells confirmed a germline T790M mutation in the patient (C) and in her mother (D). A cartoon of the location of the common mutations in the tyrosine kinase domain of the EGFR gene is shown in the upper part of the figure.